Přejít k obsahu
Merck
  • Dose of GnRH agonist (nafarelin acetate) affects intrafollicular PAPP-A expression in controlled ovarian hyperstimulation cycle.

Dose of GnRH agonist (nafarelin acetate) affects intrafollicular PAPP-A expression in controlled ovarian hyperstimulation cycle.

European journal of obstetrics, gynecology, and reproductive biology (2003-12-23)
JiHyun Suh, EunYoung Lee, SeongSoo Hwang, Sarah Yoon, Byung Koo Yoon, DukSoo Bae, DooSeok Choi
ANOTACE

To determine the effect of dose of GnRH agonist on the follicular environment in controlled ovarian hyperstimulation (COH) cycles. Twenty-eight IVF patients with normal ovarian function were divided into three groups: group I received GnRHa (nafarelin acetate/Synarel) intranasally at 200 microg daily, group II received 400 microg daily until hCG injection, and group III was given 400 microg daily before the initiation of ovarian stimulation, then 200 microg daily before the day of hCG injection. Serum estradiol, progesterone, and leptin levels were measured on the day of hCG injection. After aspiration, expression of pregnancy-associated alpha-plasma protein (PAPP)-A in the follicular fluid of dominant follicles (>20 mm) was determined by Western blot analysis. No significant difference was noted in serum estradiol, progesterone, and leptin levels. But intrafollicular PAPP-A expression was significantly higher in group II compared to other groups (P<0.05). The dose of GnRHa may have an impact on the intrafollicular environment of dominant follicles in COH cycles.

MATERIÁLY
Číslo produktu
Značka
Popis produktu

Sigma-Aldrich
Nafarelin acetate salt hydrate, ≥95% (HPLC), solid